Thales to Deliver Digital Licence Solution to Queensland, Australia
7.1.2020 16:40:00 EET | Business Wire | Press release
Thales has signed a contract to partner with Queensland’s Department of Transport and Main Roads (TMR) in Australia and local Queensland SMEs, Code Heroes and Aliva, to design, develop and deliver the State’s first Digital Licence App.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005628/en/
Thales Gemalto Digital ID Wallet (Photo: Thales)
Thales worked closely with TMR and their customers to co-design a fully integrated app-based solution that is able to manage multiple digital credentials from various sources. The comprehensive solution that integrates a backend platform with managed services, builds upon Gemalto’s next generation Digital ID Platform and Wallet technology, a globally proven and secure, smartphone-based home for all of the owner's digital identity credentials.
Thales completed the acquisition of Gemalto in April 2019 during the TMR procurement process, acquiring a set of highly complementary technologies and competencies, and reinforcing Thales’s status as a world-leader in digital identity and security.
The all-in-one Digital Licence solution utilises a privacy enhanced app that acts as a secure digital vault to store a wide range of digitalized official documents, starting with the owner’s Driver’s Licence, Photo Identification Card, Marine Licence and vehicle registration. The innovative solution delivers ease of access via a smartphone, while ensuring the owner has complete control over their personal data and the freedom to decide exactly what information to share, with whom, and when.
The app will also provide Queenslanders with a secure gateway to access TMR’s online services, supporting the opportunity to expand to other State Government online services in the future.
The innovative solution will be piloted in the Fraser Coast in early 2020, before extending to other regional locations and becoming available to over 3.7 million Queenslanders state-wide.
A first for Australia, Queensland’s Digital Licence will meet the International ISO-Compliant Mobile Driving Licence Standard, allowing the State’s digital driver’s licences to be recognised and used in over 18 countries world-wide including the US, UK and France.
Thales Australia CEO, Chris Jenkins said
“We are excited to be partnering with the Queensland Government to deliver our secure Digital ID Wallet solution. This is the first major contract award in Australia that has resulted from the merger of Thales and Gemalto. The bringing together of two technology powerhouses has strengthened Thales’s position as a world leader in digital security. The Queensland Digital Licence end-to-end solution contract is a demonstration of the success of the integration.”
Note to Editors
Gemalto's solutions are at the heart of modern life, from payments to enterprise security and the internet of things. They authenticate people, transactions and objects, encrypt data and create value for software - enabling companies and governments to deliver secure digital services for billions of individuals and things.
About Thales
The people who make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary, high-technology solutions. Solutions that make tomorrow possible today. From the bottom of the oceans to the depths of space and cyberspace, we help our customers think smarter and act faster – mastering ever greater complexity at every decisive moment along the way.
Thales generated revenues of €19 billion in 2018 with 80 thousand employees in 68 countries.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005628/en/
Contact information
Thales Digital Identity & Security
Vanessa Viala
+33 607340034
Vanessa.Viala@thalesgroup.com
Thales Australia
Jasmin Hilleard
+61 420 903 636
Jasmin.Hilleard@thalesgroup.com.au
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom